Determination of plasma metformin by a new cation-exchange HPLC technique

Anna Rita Bonfigli, Silvana Manfrini, Franco Gregorio, Roberto Testa, Ivano Testa, Giuseppina De Sio, Gilberto Coppa

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Metformin is an oral antihyperglycemic agent used in the therapy of noninsulin-dependent diabetic patients. This biguanide can induce dangerous complications such as lactic acidosis when its plasma concentration is too high. For this reason, the determination of plasma metformin should always be done during treatment. We developed a new HPLC method, for the routine determination of plasma metformin, with good reliability, rapid execution, and low costs. Sample preparation involved precipitation of the plasma proteins containing the internal standard buformin with a mixture of methanol, zinc sulfate, and ethylene glycol; the diluted supernatant was injected into a cation-exchange column. The mobile phase was potassium dihydrogenphosphate buffer-containing acetonitrile. The eluent was monitored at 236 nm. The calibration curve is linear within the range of 20-4000 ng/mL; the within-day coefficients of variation were less than 2.2% for metformin and 1.5% for buformin; the day-to-day coefficients of variation were less than 2.5% for metformin and 1.9% for buformin. The mean recoveries obtained from supplemented samples were included between 99.4 and 104.2% for metformin. Many characteristics make this method useful and easily accessible to all clinical laboratories equipped with HPLC instrumentation.

Original languageEnglish
Pages (from-to)330-334
Number of pages5
JournalTherapeutic Drug Monitoring
Volume21
Issue number3
DOIs
Publication statusPublished - Jun 1999

Fingerprint

Metformin
Cations
Buformin
High Pressure Liquid Chromatography
Plasmas
Clinical laboratories
Biguanides
Zinc Sulfate
Lactic Acidosis
Ethylene Glycol
Hypoglycemic Agents
Calibration
Methanol
Blood Proteins
Potassium
Buffers
Costs and Cost Analysis
Recovery
Therapeutics
Costs

Keywords

  • Diabetes mellitus
  • HPLC
  • Metformin

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Health, Toxicology and Mutagenesis
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health
  • Pharmacology
  • Toxicology

Cite this

Determination of plasma metformin by a new cation-exchange HPLC technique. / Bonfigli, Anna Rita; Manfrini, Silvana; Gregorio, Franco; Testa, Roberto; Testa, Ivano; De Sio, Giuseppina; Coppa, Gilberto.

In: Therapeutic Drug Monitoring, Vol. 21, No. 3, 06.1999, p. 330-334.

Research output: Contribution to journalArticle

Bonfigli, Anna Rita ; Manfrini, Silvana ; Gregorio, Franco ; Testa, Roberto ; Testa, Ivano ; De Sio, Giuseppina ; Coppa, Gilberto. / Determination of plasma metformin by a new cation-exchange HPLC technique. In: Therapeutic Drug Monitoring. 1999 ; Vol. 21, No. 3. pp. 330-334.
@article{849a4c77f39e4b5ea56918532006eb40,
title = "Determination of plasma metformin by a new cation-exchange HPLC technique",
abstract = "Metformin is an oral antihyperglycemic agent used in the therapy of noninsulin-dependent diabetic patients. This biguanide can induce dangerous complications such as lactic acidosis when its plasma concentration is too high. For this reason, the determination of plasma metformin should always be done during treatment. We developed a new HPLC method, for the routine determination of plasma metformin, with good reliability, rapid execution, and low costs. Sample preparation involved precipitation of the plasma proteins containing the internal standard buformin with a mixture of methanol, zinc sulfate, and ethylene glycol; the diluted supernatant was injected into a cation-exchange column. The mobile phase was potassium dihydrogenphosphate buffer-containing acetonitrile. The eluent was monitored at 236 nm. The calibration curve is linear within the range of 20-4000 ng/mL; the within-day coefficients of variation were less than 2.2{\%} for metformin and 1.5{\%} for buformin; the day-to-day coefficients of variation were less than 2.5{\%} for metformin and 1.9{\%} for buformin. The mean recoveries obtained from supplemented samples were included between 99.4 and 104.2{\%} for metformin. Many characteristics make this method useful and easily accessible to all clinical laboratories equipped with HPLC instrumentation.",
keywords = "Diabetes mellitus, HPLC, Metformin",
author = "Bonfigli, {Anna Rita} and Silvana Manfrini and Franco Gregorio and Roberto Testa and Ivano Testa and {De Sio}, Giuseppina and Gilberto Coppa",
year = "1999",
month = "6",
doi = "10.1097/00007691-199906000-00015",
language = "English",
volume = "21",
pages = "330--334",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Determination of plasma metformin by a new cation-exchange HPLC technique

AU - Bonfigli, Anna Rita

AU - Manfrini, Silvana

AU - Gregorio, Franco

AU - Testa, Roberto

AU - Testa, Ivano

AU - De Sio, Giuseppina

AU - Coppa, Gilberto

PY - 1999/6

Y1 - 1999/6

N2 - Metformin is an oral antihyperglycemic agent used in the therapy of noninsulin-dependent diabetic patients. This biguanide can induce dangerous complications such as lactic acidosis when its plasma concentration is too high. For this reason, the determination of plasma metformin should always be done during treatment. We developed a new HPLC method, for the routine determination of plasma metformin, with good reliability, rapid execution, and low costs. Sample preparation involved precipitation of the plasma proteins containing the internal standard buformin with a mixture of methanol, zinc sulfate, and ethylene glycol; the diluted supernatant was injected into a cation-exchange column. The mobile phase was potassium dihydrogenphosphate buffer-containing acetonitrile. The eluent was monitored at 236 nm. The calibration curve is linear within the range of 20-4000 ng/mL; the within-day coefficients of variation were less than 2.2% for metformin and 1.5% for buformin; the day-to-day coefficients of variation were less than 2.5% for metformin and 1.9% for buformin. The mean recoveries obtained from supplemented samples were included between 99.4 and 104.2% for metformin. Many characteristics make this method useful and easily accessible to all clinical laboratories equipped with HPLC instrumentation.

AB - Metformin is an oral antihyperglycemic agent used in the therapy of noninsulin-dependent diabetic patients. This biguanide can induce dangerous complications such as lactic acidosis when its plasma concentration is too high. For this reason, the determination of plasma metformin should always be done during treatment. We developed a new HPLC method, for the routine determination of plasma metformin, with good reliability, rapid execution, and low costs. Sample preparation involved precipitation of the plasma proteins containing the internal standard buformin with a mixture of methanol, zinc sulfate, and ethylene glycol; the diluted supernatant was injected into a cation-exchange column. The mobile phase was potassium dihydrogenphosphate buffer-containing acetonitrile. The eluent was monitored at 236 nm. The calibration curve is linear within the range of 20-4000 ng/mL; the within-day coefficients of variation were less than 2.2% for metformin and 1.5% for buformin; the day-to-day coefficients of variation were less than 2.5% for metformin and 1.9% for buformin. The mean recoveries obtained from supplemented samples were included between 99.4 and 104.2% for metformin. Many characteristics make this method useful and easily accessible to all clinical laboratories equipped with HPLC instrumentation.

KW - Diabetes mellitus

KW - HPLC

KW - Metformin

UR - http://www.scopus.com/inward/record.url?scp=0032968309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032968309&partnerID=8YFLogxK

U2 - 10.1097/00007691-199906000-00015

DO - 10.1097/00007691-199906000-00015

M3 - Article

C2 - 10365648

AN - SCOPUS:0032968309

VL - 21

SP - 330

EP - 334

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 3

ER -